US EditionKelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
- On May 12, 2025, Kelyniam Global, Inc. From Canton, Connecticut reported its earnings for the quarter ending March 31, 2025, and revealed a new partnership aimed at supporting future growth.
- The company encountered difficulties in the first quarter as fluctuations in seasonal demand and the scheduling of surgeries postponed revenue recognition, negatively impacting its financial results.
- Kelyniam reported total revenue of $624,910, a 34.7% decrease from Q1 2024, along with a gross margin of $470,940 and an operating loss of $140,556.
- Kelyniam secured a partnership lasting three years with Singapore-based Osteopore Ltd., allowing it to distribute Osteopore’s bioresorbable regenerative implant products—such as Osteostrip, Osteoplug, and Osteomesh—across the U.S. Market.
- The collaboration and expanded sales team, highlighted by Alex Rivero’s appointment and plans to add more distributors, are designed to establish Kelyniam at the forefront of regenerative cranial medicine in the U.S.
Insights by Ground AI
Does this summary seem wrong?
70 Articles
70 Articles
All
Left
7
Center
23
Right
9
Daily News-Record+69 Reposted by 69 other sources
Kelyniam Global Announces Q1 2025 Financial Results and Strategic Partnership
CANTON, Conn., May 12, 2025 /PRNewswire/ -- Kelyniam Global, Inc. (OTC: KLYG), a leading manufacturer of custom cranial and craniofacial implants, today announced its financial results for the first quarter ended March 31, 2025, and highlighted a new partnership to…
Coverage Details
Total News Sources70
Leaning Left7Leaning Right9Center23Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 18%
C 59%
R 23%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
